Vaxon Biotech specializes in anti-tumor immunotherapy through an innovative therapeutic approach which aims to stimulate the immune system to target and destroy tumor cells and halt tumor development. The company is currently developing four products, two in clinical development and two at the preclinical stage. The most advanced product in its portfolio, Vx-001, is a peptide based vaccine for HLA-A2-positive patients with TERT-expressing tumors. It has been in phase IIB trials for non-small-cell lung cancer (NSCLC) since 2012 (underway in eight European countries).